Loading...
01/11 11:50
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
Trailing 12-month revenue $16.7 million, up from $13.8 million, reflecting strong operational execution and customer growth.
Q2 2025 Net Revenue $4.4 million, a 36% increase year-over-year, driven by growth in programmatic and emergency response businesses.
First Half 2025 Revenue $9.3 million, a 37% increase year-over-year, attributed to strong performance across all regions and programmatic business growth.
Gross Margins (Q2 2025) 63%, up from 59% in Q2 2024, due to reduced shipping costs and inventory reserve adjustments.
Research and Development Expenses (Q2 2025) $311,000, up from $254,000 in Q2 2024, due to increased headcount.
Sales, General and Administrative Expenses (Q2 2025) $2.2 million, up 13% from $1.9 million in Q2 2024, driven by higher sales commissions, employee bonuses, and stock compensation expenses.
Net Income (Q2 2025) $237,000, compared to a net loss of $289,000 in Q2 2024, reflecting improved profitability.
Adjusted EBITDA (Q2 2025) $355,000, compared to a loss of $133,000 in Q2 2024, indicating better operational performance.
Net Cash Provided by Operating Activities (Q2 2025) $994,000, an improvement of $1.495 million from the prior year, driven by positive net income, decreased accounts receivable, and increased accrued expenses.
First Half 2025 Gross Margins 64%, up from 61% in the prior year, due to favorable product mix and reduced inventory reserve adjustments.
First Half 2025 Net Income $795,000, compared to a net loss of $458,000 in the prior year, reflecting strong revenue growth and cost management.
First Half 2025 Adjusted EBITDA $1.022 million, compared to a loss of $228,000 in the prior year, showing improved financial performance.
Cash Balance (June 30, 2025) $5.1 million, up from $3.8 million as of December 31, 2024, with the company remaining debt-free.
S100 microfilter and 20-inch HydraGuard: These new products have unlocked opportunities across cell processing, labs, and beyond.
Expansion into underserved verticals: Focused on dental, government, and municipal facilities.
Revenue growth: Trailing 12-month revenue grew from $13.8 million to $16.7 million, with Q2 revenue at $4.4 million, a 36% increase over Q2 2024.
Profitability: Achieved third consecutive quarter of profitability with net income of $237,000 in Q2 2025.
Gross margins: Improved to 63% in Q2 2025 from 59% in Q2 2024, driven by reduced shipping costs and inventory reserve adjustments.
Customer base: Active customer sites grew to over 1,600, with the highest retention rate in the past 6 quarters.
Cash flow: Net cash provided by operating activities was $994,000 in Q2 2025, an improvement of $1.495 million compared to Q2 2024.
Sales team expansion: Strategic expansion into non-healthcare verticals has started yielding results.
Filter tracking app: Increased customer adoption has improved visibility, compliance, and support, with thousands of filters now being tracked.
Regulatory Requirements: The company faces challenges related to existing and new regulatory requirements, which could impact its business operations and compliance costs.
Market Adoption: The rate of adoption of the company's products and services by hospitals and other healthcare providers remains a critical factor for success, posing a risk if adoption rates slow.
Commercialization Efforts: The success of commercialization efforts is essential, and any failure in these efforts could adversely affect revenue growth and market penetration.
Economic and Competitive Factors: Economic uncertainties and competitive pressures in the market could negatively impact the company's performance and strategic objectives.
Operational Discipline: Maintaining operational discipline while scaling and protecting profitability is a challenge that could affect the company's financial stability.
Supply Chain Costs: Although shipping costs have decreased, any future increases in supply chain costs could impact gross margins and profitability.
R&D Expenses: Increased research and development expenses due to higher headcount could strain financial resources if not managed effectively.
Expansion into underserved verticals: The company plans to expand into underserved verticals such as dental, government, and municipal facilities.
New product innovations: Nephros is bringing new innovations to market, including the S100 microfilter and 20-inch HydraGuard, which are expected to unlock opportunities across cell processing, labs, and other areas.
Operational discipline and profitability: The company aims to execute with operational discipline while continuing to protect profitability.
The selected topic was not discussed during the call.
Nephros shows strong financial performance with significant improvements in net income and adjusted EBITDA. The strategic expansion into underserved markets, innovative product launches, and maintaining a solid cash position are positive indicators. The Q&A highlights growth drivers in infection control and innovations tackling PFAS and microplastics, with a positive outlook on margins despite tariffs. However, lack of specific guidance on PFAS revenue and tariff impacts slightly tempers enthusiasm. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
The earnings call reveals strong financial performance with increased revenue, improved margins, and positive net income, despite some economic and competitive pressures. The company's strategic initiatives, including market expansion and digital tool development, are progressing well. The Q&A section indicates potential growth opportunities, although some responses were vague. The absence of shareholder return plans is a minor negative. Overall, the positive financial results and strategic growth initiatives suggest a positive stock price movement.
The earnings call reflects strong financial performance with a significant increase in net income and improved margins, despite some economic concerns. The Q&A section reveals optimism in new product opportunities and market expansion, though management was vague on certain details. Overall, the positive financial results and growth potential suggest a likely positive stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
